Radiotherapy and short-term androgen deprivation for localized prostate cancer.

By Christopher U. Jones, D. Hunt, D. McGowan, M. Amin, M. Chetner, D. Bruner, M. Leibenhaut, S. Husain, M. Rotman, L. Souhami and 2 more. New England Journal of Medicine, 2011

629 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Urology

View Paper: https://www.semanticscholar.org/paper/0a346f37ede5acc43b82224eae34360e3df06715

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Michel Bolla
2. N. Mottet
3. J. Bellmunt
4. V. Matveev
5. Steven Joniau
6. Thomas Wiegel

Citations in the corpus

• Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy (2012, neutral): “Other clinical studies for which ROS have been shown to play a role in radiation-induced therapy include patients with prostate cancer (148), NSCLC (104, 107, 144, 290), rectal cancer (81), and breast cancer (309).”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017, background): “Patients suitable for ADT should be given combined doseescalated IMRT (76–78 Gy) with short-term ADT (4–6 mo) [70].”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020, methodology): “Patients suitable for ADT should be given combined dose-escalated IMRT (76 – 78 Gy) or moderate hypofractionated RT with short-term ADT (4 – 6 mo) [155].”